Telavancin Hydrochloride ASHP INJECTABLE DRUG INFORMATION

1472 Telavancin Hydrochloride ASHP INJECTABLE DRUG INFORMATION

Telavancin Hydrochloride AHFS 8:12.28.16

Products is recommended.2831 For doses outside this range, dilution to a concentration of 0.6 to 8 mg/mL is recommended.2831 The manu- Telavancin hydrochloride is available as a lyophilized powder facturer recommends dilution in dextrose 5%; sodium chloride in single-use vials containing telavancin 250 and 750 mg as the 0.9%; or Ringer’s injection, lactated.2831 hydrochloride.2831 Also present are hydroxypropyl-beta-cyclo- dextrin, mannitol, and sodium hydroxide and hydrochloric acid to adjust pH.2831 Stability Intact vials of telavancin hydrochloride should be stored under The 250-mg vial should be reconstituted with 15 mL and the refrigeration.2831 The reconstituted drug in the vial and the 750-mg vial with 45 mL of dextrose 5%, sterile water for injection, diluted solution in the infusion bag should be used within 12 or sodium chloride 0.9% and mixed thoroughly to yield a telavancin hours if stored at room temperature or 7 days if stored under concentration of 15 mg/mL.2831 To minimize foaming during recon- refrigeration.2831 3097 The total time for the reconstituted drug stitution, allow the vacuum of the vial to draw the diluent from the in the vial and the diluted solution in the infusion bag together syringe into the vial; do not forcefully inject the diluent.2831 Any vial should not exceed 12 hours at room temperature or 7 days that does not have a vacuum should be discarded.2831 Dissolution under refrigeration.2831 3097 may occasionally require up to 20 minutes.2831 Do not forcefully shake the vial or the diluted solution in the infusion bag.2831 Freezing Solutions pH The manufacturer states that the diluted solution of telavancin in the infusion bag can be stored at −30 to −10°C for up From 4 to 5.2831 to 32 days.2831 Telavancin (Ben Venue) 0.6 and 8 mg/mL diluted Trade Name(s) in sodium chloride 0.9% or dextrose 5% in polyvinyl chloride (PVC) and non-PVC infusion bags and stored at −20°C exhib- Vibativ ited less than 10% loss of the drug during the 32-day study period.3096 The authors recommended that solutions be brought Administration to room temperature without any assistance (e.g., sonication, Telavancin is administered by intravenous infusion over 60 hot water bath) and used immediately after thawing, or within minutes after dilution in a compatible infusion solution.2831 For 12 hours at room temperature; thawed solutions should not be telavancin doses of 150 to 800 mg, dilution in 100 to 250 mL refrozen.3096

Compatibility Information Solution Compatibility

Telavancin HCl

Test Soln Name Mfr Mfr Conc/L or % Remarks Ref C/I

Dextrose 5% ASP Use within 12 hr at room temperature or 7 days refrigerated 2831 C

Dextrose 5% BAa BV 0.6 and 8 g Stable for 12 hr in ambient conditions or 7 days at 2 to 8°C without light 3097 C

Dextrose 5% BAa BV 0.6 and 8 g Less than 10% loss in 32 days at −20°C 3096 C

Dextrose 5% BRNb BV 0.6 and 8 g Less than 10% loss in 32 days at −20°C 3096 C

Ringer’s injection, lactated ASP Use within 12 hr at room temperature or 7 days refrigerated 2831 C

Ringer’s injection, lactated BAa BV 0.6 and 8 g Stable for 12 hr in ambient conditions or 7 days at 2 to 8°C without light 3097 C

Sodium chloride 0.9% ASP Use within 12 hr at room temperature or 7 days refrigerated 2831 C

Sodium chloride 0.9% BAa BV 0.6 and 8 g Stable for 12 hr in ambient conditions or 7 days at 2 to 8°C without 3097 C light

Sodium chloride 0.9% BAa BV 0.6 and 8 g Less than 10% loss in 32 days at −20°C 3096 C

Sodium chloride 0.9% BRNb BV 0.6 and 8 g Less than 10% loss in 32 days at −20°C 3096 C a Tested in PVC containers. b Tested in non-PVC containers.

DOI: 10.37573/9781585286850.369 ASHP INJECTABLE DRUG INFORMATION Telavancin Hydrochloride 1473

Y-Site Injection Compatibility (1:1 Mixture)

Telavancin HCl

Test Drug Mfr Conc Mfr Conc Remarks Ref C/I

Amphotericin B XGN 0.1 mg/mLa ASP 7.5 mg/mLa Increase in measured turbidity 2830 I

Amphotericin B lipid complex ENZ 1 mg/mLa ASP 7.5 mg/mLa Physically compatible for 2 hr 2830 C

Amphotericin B liposomal ASP 1 mg/mLa ASP 7.5 mg/mLa Increase in measured turbidity 2830 I

Ampicillin sodium–sulbactam sodium BA 20 mg/mLa b c e ASP 7.5 mg/mLa b c Physically compatible for 2 hr 2830 C

Azithromycin APP 2 mg/mLa b c ASP 7.5 mg/mLa b c Physically compatible for 2 hr 2830 C

Calcium gluconate APP 40 mg/mLa b c ASP 7.5 mg/mLa b c Physically compatible for 2 hr 2830 C

Caspofungin acetate ME 0.5 mg/mLb ASP 7.5 mg/mLb Physically compatible for 2 hr 2830 C

Cefepime HCl SAG 40 mg/mLa b c ASP 7.5 mg/mLa b c Physically compatible for 2 hr 2830 C

Ceftazidime HOS 40 mg/mLa b c ASP 7.5 mg/mLa b c Physically compatible for 2 hr 2830 C

Ceftriaxone sodium HOS 20 mg/mLa b ASP 7.5 mg/mLa b Physically compatible for 2 hr 2830 C

Ciprofloxacin HOS 2 mg/mLa ASP 7.5 mg/mLa Physically compatible for 2 hr 2830 C

Colistimethate sodium PAD 4.5 mg/mLa ASP 7.5 mg/mLa Visible turbidity formed 2830 I

Colistimethate sodium PAD 4.5 mg/mLb c ASP 7.5 mg/mLb c Physically compatible for 2 hr 2830 C

Cyclosporine BED 5 mg/mLb c ASP 7.5 mg/mLb c Increase in measured turbidity 2830 I

Cyclosporine BED 5 mg/mLa ASP 7.5 mg/mLa Physically compatible for 2 hr 2830 C

Dexamethasone sodium phosphate AMR 1 mg/mLa b c ASP 7.5 mg/mLa b c Physically compatible for 2 hr 2830 C

Digoxin BA 0.25 mg/mL ASP 7.5 mg/mLa b c Visible turbidity formed 2830 I

Diltiazem HCl BED 5 mg/mL ASP 7.5 mg/mLa b c Physically compatible for 2 hr 2830 C

Dobutamine HCl HOS 4 mg/mLa b c ASP 7.5 mg/mLa b c Physically compatible for 2 hr 2830 C

Dopamine HCl HOS 3.2 mg/mLa b c ASP 7.5 mg/mLa b c Physically compatible for 2 hr 2830 C

Doripenem OMN 10 mg/mLa b ASP 7.5 mg/mLa b Physically compatible for 2 hr 2830 C

Doxycycline hyclate APP 1 mg/mLa b c ASP 7.5 mg/mLa b c Physically compatible for 2 hr 2830 C

Ertapenem sodium ME 20 mg/mLb ASP 7.5 mg/mLb Physically compatible for 2 hr 2830 C

Esomeprazole sodium ASZ 0.4 mg/mLa b c ASP 7.5 mg/mLa b c Discoloration and increase in 2830 I measured turbidity

Famotidine BED 2 mg/mLa b c ASP 7.5 mg/mLa b c Physically compatible for 2 hr 2830 C

Fluconazole SAG 2 mg/mLb ASP 7.5 mg/mLb Physically compatible for 2 hr 2830 C

Furosemide HOS 3 mg/mLa b c ASP 7.5 mg/mLa b c Immediate precipitation 2830 I

Gentamicin sulfate HOS 5 mg/mLa b c ASP 7.5 mg/mLa b c Physically compatible for 2 hr 2830 C

Heparin sodium APP 1000 units/mL ASP 7.5 mg/mLa b Measured turbidity increased 2830 I

Heparin sodium APP 1000 units/mL ASP 7.5 mg/mLc Physically compatible for 2 hr 2830 C

Hydrocortisone sodium succinate PF 1 mg/mLa b c ASP 7.5 mg/mLa b c Physically compatible for 2 hr 2830 C

Imipenem–cilastatin sodium ME 5 mg/mLa g ASP 7.5 mg/mLa Slight measured turbidity 2830 I increase

Imipenem–cilastatin sodium ME 5 mg/mLb g ASP 7.5 mg/mLb Physically compatible for 2 hr 2830 C

Labetalol HCl BED 5 mg/mLa b c ASP 7.5 mg/mLa b c Physically compatible for 2 hr 2830 C